191 related articles for article (PubMed ID: 15564232)
21. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
[No Abstract] [Full Text] [Related]
22. Safety concerns of angiotensin II receptor blockers in preschool children.
Tullus K
Arch Dis Child; 2011 Sep; 96(9):881-2. PubMed ID: 21690106
[TBL] [Abstract][Full Text] [Related]
23. Second study on valsartan is threatened with retraction over alleged data manipulation.
Mahony C
BMJ; 2013 Aug; 347():f4920. PubMed ID: 23918698
[No Abstract] [Full Text] [Related]
24. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
[TBL] [Abstract][Full Text] [Related]
25. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
[TBL] [Abstract][Full Text] [Related]
26. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
London G; Schmieder R; Calvo C; Asmar R
Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
[TBL] [Abstract][Full Text] [Related]
27. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
28. Amlodipine + valsartan + hydrochlorothiazide. A 3-drug fixed-dose combination for hypertension: too many drawbacks.
Prescrire Int; 2011 Mar; 20(114):67. PubMed ID: 21648225
[No Abstract] [Full Text] [Related]
29. Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption.
Sawada Y; Yoshiki R; Kawakami C; Fukamachi S; Sugita K; Nakamura M; Tokura Y
Acta Derm Venereol; 2010 Sep; 90(5):521-2. PubMed ID: 20814632
[No Abstract] [Full Text] [Related]
30. [First fixed combination of sartan and high-dosage diuretic. A strong duo against high blood pressure].
MMW Fortschr Med; 2004 Apr; 146(14):45. PubMed ID: 15344757
[No Abstract] [Full Text] [Related]
31. Angiotensin receptor blockers: baseline therapy in hypertension?
Messerli FH; Bangalore S; Ruschitzka F
Eur Heart J; 2009 Oct; 30(20):2427-30. PubMed ID: 19723696
[No Abstract] [Full Text] [Related]
32. [Cross reactivity between ACE inhibitors and angiotensin receptor blockers].
Rosenborg S
Lakartidningen; 2010 Feb 17-23; 107(7):444. PubMed ID: 20384078
[No Abstract] [Full Text] [Related]
33. [Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
MMW Fortschr Med; 2006 Feb; 148(5):48-9. PubMed ID: 16518941
[No Abstract] [Full Text] [Related]
34. Valsartan, captopril, or both in myocardial infarction.
Jorde UP
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
[No Abstract] [Full Text] [Related]
35. Valsartan, captopril, or both in myocardial infarction.
Moshenyat R; Kupfer Y; Tessler S
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988935
[No Abstract] [Full Text] [Related]
36. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
Corea L; Cardoni O; Fogari R; Innocenti P; Porcellati C; Provvidenza M; Meilenbrock S; Sullivan J; Bodin F
Clin Pharmacol Ther; 1996 Sep; 60(3):341-6. PubMed ID: 8841157
[TBL] [Abstract][Full Text] [Related]
37. Warnings against candesartan in pregnancy are not implemented in physicians' practice.
Borthen C; Oglaend B; Eggebøe T; Ellingsen CL; Schjøtt J
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):235. PubMed ID: 19615811
[No Abstract] [Full Text] [Related]
38. Increased renal echogenicity in a preterm neonate. Kidneys with tubular dysplasia due to exposure to candesartan during pregnancy.
Bald M; Holder M; Zieger M; Vochem M; Leichter HE
Pediatr Nephrol; 2005 Nov; 20(11):1664-5, 1666-8. PubMed ID: 16082550
[No Abstract] [Full Text] [Related]
39. [Risk oriented therapy of hypertension. Lowering blood pressure and risk].
MMW Fortschr Med; 2007 Nov; 149(46):53. PubMed ID: 18069196
[No Abstract] [Full Text] [Related]
40. Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: case report and literature review.
Kalra A; Cooley C; Palaniswamy C; Kalra A; Zanotti-Cavazzoni SL
Am J Ther; 2012 Nov; 19(6):e189-92. PubMed ID: 20838200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
